Korean Chinese Japanese
  • Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Korean Chinese Japanese
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Pharma & Bio
Technology

[Big Tech Enters New Drug Development: Part 1] Google Becomes First Big Tech Company to Conduct 'In-House Clinical Trials'… Will This Shake Up the New Drug Development Landscape?

Isomorphic Labs, a spin-off from Google DeepMind, is reportedly on the verge of entering the first human clinical trial for a new cancer drug designed using artificial intelligence (AI). If successful…
  • 2026-09-24 11:01:01
  • Kim Seung-kwon
Business·Industry

Cellid and BlueMtec Rally on Change-of-Control Deals; Inventera Gains [K-bio pulse]

On September 22, changes in control at biotech companies drew significant attention across South Korea’s pharmaceutical and biotech sectors. Vaccine developer Cellid surged after announcing a deal wit…
  • 2026-09-24 08:37:03
  • Kim Jinsoo
Business·Industry

Cellid Co., Ltd. and BLUEMTEC CO., LTD. See Volatility on News of Management Control Sale… Inventera Inc. Rises [Bio Spotlight]

On the 22nd, news of management control sales by biotech companies drew significant attention in the pharmaceutical and biotech industry. Shares of vaccine developer Cellid Co., Ltd. surged after it a…
  • 2026-09-24 08:37:02
  • Kim Jinsoo
Technology

Japanese Stroke AI Expert: "Korean Medical AI Technologies, Such as JLK, Inc., Play a Major Role in Japan"

"I was impressed by South Korea's AI medical technology. If accurate, clear, and objective indicators are automatically provided, it could significantly reduce the burden on medical staff in the treat…
  • 2026-09-23 11:02:03
  • Kim Seung-kwon
Technology

SkyLabs Hits Upper Price Limit on U.S. Interest; Orum Therapeutics Extends Its Decline [K-Bio Pulse]

SkyLabs Hits Upper Price Limit on U.S. Attention; Orum Therapeutics Extends SlideSouth Korea’s pharmaceutical and biotech sector saw notable movements on September 21, led by SkyLabs, which hit the up…
  • 2026-09-23 08:02:02
  • KIM SUNG-JIN
Technology

SkyLabs Rises on U.S. Attention… Orum Therapeutics, Inc. Falls for the Second Consecutive Day [Bio Spotlight]

On the 21st, in the pharmaceutical and biotech sector, #SkyLabs stood out the most, hitting the daily price limit after a nine-trading-day downtrend. SkyLabs is a digital healthcare company that manuf…
  • 2026-09-23 08:01:02
  • KIM SUNG-JIN
Technology

National Health Insurance to Cover CGM for Type 2 Diabetes… Can i-SENS, Inc. Break Through Low Market Penetration?

The government has expanded health insurance coverage for continuous glucose monitors (CGMs) to include patients with severe type 2 diabetes, marking a turning point that is expected to boost the low …
  • 2026-09-22 08:11:02
  • NA EUN-KYUNG
Lifestyle

LAMEDITECH Co., Ltd. Enters the Skin Booster Market… Overcoming the Limitations of a Latecomer Through a Platform Strategy

LAMEDITECH Co., Ltd.(462510), a company specializing in laser beauty and medical devices, is entering the extracellular matrix (ECM) skin booster business, which has rapidly emerged as a new paradigm …
  • 2026-09-22 08:01:02
  • YU JIN-HEE
Technology

Orum Plunges on Clinical Trial Halt; ENCell and VUNO Jump [K-Bio Pulse]

South Korean biotech stocks saw sharp divergence on September 18, as Orum Therapeutics, Inc. plunged to the daily lower limit following another clinical setback, while ENCell Co., Ltd. and VUNO Inc. p…
  • 2026-09-22 07:02:03
  • KIM SAE-MI
Technology

No Respite for K-Bio… Shares Plunge on ‘Clinical Trial Suspension Shock’ [Bio Insight]

On the 18th, the biotech sector was rocked by the shock of #Orum Therapeutics, Inc.’s decision to halt clinical development. Amid this turmoil, some stocks—including #ENCell Co., Ltd. and VUNO, Inc.(3…
  • 2026-09-22 07:02:02
  • KIM SAE-MI
prev 21 22 23 24 25 26 27 28 29 30 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea China Japan
English